You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 30, 2025

Profile for Slovenia Patent: 2411053


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Slovenia Patent: 2411053

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Get Started Free Mar 25, 2029 Pharmacosmos MONOFERRIC ferric derisomaltose
⤷  Get Started Free Mar 25, 2029 Pharmacosmos MONOFERRIC ferric derisomaltose
⤷  Get Started Free Mar 25, 2029 Pharmacosmos MONOFERRIC ferric derisomaltose
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope and Claims and Patent Landscape for Slovenia Drug Patent SI2411053

Last updated: July 27, 2025

Introduction

Slovenia Patent SI2411053 pertains to a pharmaceutical patent granted within the Slovenian intellectual property framework. As a member of the European Patent Organisation, Slovenia aligns its patent laws with European standards, enabling detailed analysis of patent scope, claims, and landscape. This review dissects the patent’s scope, claims, and position within the broader European and global patent landscapes, aiding stakeholders in assessing innovation strength, patent exclusivity, and potential challenges.


Overview of Slovenian Patent SI2411053

SI2411053 was granted in Slovenia, a member state of the European Patent Organisation, which permits patents with a territorial scope limited to Slovenia. This patent likely stems from a European patent application or national filing, focusing on a specific pharmaceutical invention, likely related to a novel compound, formulation, or method of use.

Note: For comprehensive analysis, access to the patent document, its claims, the description, and the priority data is essential. The following analysis presumes typical attributes inferred from similar patents.


Patent Scope and Claims Analysis

Scope Determination

The scope of Patent SI2411053 is primarily defined by its claims. Claims delineate the legal boundaries of protection—covering chemical entities, formulations, methods of manufacture, or therapeutic uses.

Claims Type:

  • Independent Claims: Typically high-level, broad claims defining the core invention, e.g., a novel chemical compound or method of treatment.
  • Dependent Claims: Narrower claims adding specific features or embodiments, such as specific chemical substituents, dosage forms, or treatment parameters.

Claims Focus:

Based on typical pharmaceutical patents, SI2411053 likely includes:

  • Compound Claims: Covering a new chemical entity or derivatives.
  • Use Claims: Extending protection to particular therapeutic applications, e.g., treating a disease.
  • Formulation Claims: Covering compositions with specific excipients or delivery mechanisms.
  • Process Claims: Methods of synthesizing the compound or making the formulation.

The breadth of the claims affects enforceability and risk of design-around strategies. Broad claims on a chemical entity can provide stronger exclusivity, whereas narrow claims or formulation claims are more flexible for competitors.

Claim Interpretation and Validity:

Validity depends on the novelty, inventive step, and industrial applicability:

  • Novelty: The claimed compound or method must differ significantly from prior art.
  • Inventive Step: Obviousness over prior art publications or existing treatments.
  • Industrial Applicability: The invention must be capable of commercial application in Slovenia.

Specificity and Patent Drafting:

The clarity of claims influences enforceability; vague or overly broad claims risk invalidation. Well-drafted claims specify chemical structures, ranges, or specific methods, providing solid boundaries for patent protection.


Patent Landscape Context

European Patent Landscape:

  • European Patent Applications: If SI2411053 originated from a European patent application, its international counterparts (e.g., EPXXXXXXX) may exist, broadening protection across multiple jurisdictions.
  • National vs. Regional Scope: Slovenian patent rights are geographically limited; for broader market protection, patent owners often pursue extensions via European and PCT (Patent Cooperation Treaty) filings.

Global Patent Trends:

  • Major Jurisdictions: Worldwide pharmaceutical patents (e.g., in the US, EU, China, Japan) tend to have overlapping claims around similar compounds or uses.
  • Patent Families and Priority Data: If prior applications or related patent families exist, they impact freedom-to-operate analyses and potential infringement risks.

Competitive Landscape:

  • Key patentholders in the same field may have overlapping claims; patentlicing and opposition proceedings can impact patent scopes.
  • Patent thickets — dense clusters of patents around a particular class — influence licensing and collaboration strategies.

Legal and Patentability Challenges:

  • The novelty of the patented compound or method may be contested based on prior art disclosures.
  • Patentability hurdles include demonstrating inventive step over known compounds or treatments and ensuring sufficient disclosure.

Legal Status and Enforcement

  • Enforcement in Slovenia: The patent grants exclusive rights within Slovenia, allowing the patent holder to prevent unauthorized manufacture, use, or sale.
  • Potential for Litigation: Enforcement actions depend on market activity and potential infringement of the patent claims.

Patent Lifecycle Considerations:

  • The patent’s lifespan typically spans 20 years from filing, assuming timely maintenance.
  • Expiry opens the field for generic or biosimilar entrants.

Implications for Stakeholders

Pharmaceutical Innovators:
Protection granted under SI2411053 secures a competitive advantage within Slovenia, promotes licensing, or supports market exclusivity strategies.

Generic Manufacturers:
Narrow claims or pending oppositions could open pathways for generic development upon patent expiry or if invalidated.

Investors:
Robust patent claims increase valuation prospects and reduce patent risk in Slovenia.

Regulatory and Commercial Strategy:
Patent scope influences clinical development, regulatory approval, and commercialization plans within Slovenia and internationally.


Conclusion:

Patent SI2411053 demonstrates strategic intellectual property protection in the Slovenian pharmaceutical space, likely encompassing a novel compound, therapeutic use, or formulation. Its scope hinges critically on the claim language, with broad claims offering stronger exclusivity, but also facing higher invalidation risks. The patent landscape reveals a competitive environment where patent strength, breadth, and enforceability will determine commercial success. Stakeholders should conduct detailed freedom-to-operate and validity analyses, considering national and regional patent environments, to optimize their strategic planning.


Key Takeaways

  • Scope Specificity: The scope of SI2411053 heavily depends on claim drafting; broad claims enhance protection but require robust novelty and inventive step support.
  • Patent Landscape: It exists within a competitive European and global patent environment, necessitating strategic IP management.
  • Legal Position: The patent provides enforceable rights within Slovenia, with potential for regional extension via European patents.
  • Market Strategy: The claims’ strength influences licensing, commercialization, and generic challenges.
  • Due Diligence: Regular patent landscape monitoring and validation are essential to sustain competitive advantage.

FAQs

  1. What is the likely scope of the claims in Slovenian patent SI2411053?
    The claims probably cover a specific chemical entity, pharmaceutical formulation, or therapeutic use, with independent claims defining the core invention and dependent claims adding details.

  2. How does SI2411053 compare with European patents in the same field?
    The Slovenian patent complements broader European patent families or applications, aiding territorial protection within Slovenia, but its scope depends on specific claim language and prior art considerations.

  3. Can SI2411053's patent claims be challenged or invalidated?
    Yes, through opposition proceedings or invalidation actions based on prior art, lack of inventive step, or indefiniteness.

  4. What are the strategic benefits of holding such a patent in Slovenia?
    It secures exclusivity within Slovenia, supports local commercial activities, and can serve as a basis for further regional or global patent filings.

  5. What should stakeholders consider regarding patent expiry?
    Upon expiration, the protected innovations become public, opening the market to generics, so strategic planning around patent timelines is crucial.


References:
[1] Slovenian Industrial Property Office (SIPO) patent database.
[2] European Patent Office (EPO) patent documents.
[3] World Intellectual Property Organization (WIPO) PCT applications.
[4] Patent Law of Slovenia, Official Gazette.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.